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IntroductIon
The biological development and cell turnover of a tissue are 
regulated by a planned death process called apoptosis, which is 
responsible for the elimination of senescing or undesirable cells. 
This phenomenon was first described by Kerr et al. (1972)1. It is 
essential in the proliferation, differentiation, and survival of cells 
in processes of organogenesis, hematopoiesis, tissue replace-
ment, organ atrophy and metamorphosis, inflammatory response 
and secretion of cells after damage by genotoxic agents2,3. 
In the process of apoptosis, cell death is induced by the 
activation of a genetically and biochemically regulated cell death 
system, involving the participation of pro-apoptotic molecules 
(Fas, Fas-L, Bax, Caspases 2, 3, 6, 7, 8 and 9) which are able 
to cause drastic morphological and functional alterations. On 
the other hand, this process could be inhibited by the activation 
of anti-apoptotic molecules (Bcl-2, FLIP) that block the appea-
rance and evolution of these cell alterations. Thus, homeostasis 
(essential structural and functional balance for the survival of a 
cell population) depends on the balance between the activation 
of pro- and anti-apoptotic molecules4,5. 
When unregulated, apoptosis could contribute to the appea-
rance of various neoplastic, autoimmune and neurodegenerative 
diseases2,5,6.
Several apoptosis inducing and inhibiting agents are recog-
nized as potential weapons in the fight against diseases related 
to cell proliferation and cell death disorders. Among these agents, 
steroid and non-steroid hormones are particularly noteworthy. 
Steroid hormones could present both pro-apoptotic7  and anti-
apoptotic8 activity.  
Melatonin, a non-steroid hormone (indolamine) produced in 
the pineal gland. It influences the regulation of the neuroendocrine 
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AbstrACt
Apoptosis or planned cell death is a biological phenomenon that is essential for the development and 
maintenance of a cell population. In this process, senescent or damaged cells are eliminated after 
activation of a cell death program involving participation of pro-apoptotic molecules (Fas, Fas-L, Bax, 
caspases 2, 3, 6, 7, 8 and 9).  Molecule activation causes typical morphological changes, such as cell 
shrinkage, loss of adhesion to the extracellular matrix and neighboring cells, chromatin condensation, 
DNA fragmentation and formation of apoptotic bodies. Anti-apoptotic molecules (Bcl-2, FLIP) block the 
emergence and evolution of these cell changes and prevent cell death. The balance between pro- and 
anti-apoptotic molecules ensures tissue homeostasis. When apoptosis is out of control, it contributes 
to the emergence of several neoplastic, autoimmune and neurodegenerative diseases. Several inducing 
and inhibiting agents of apoptosis are recognized as potential weapons in the fight against disorders 
related to cell proliferation and death among, among which stand hormones out. Melatonin has been 
reported as an important anti-apoptotic agent in various tissues by reducing cell calcium uptake, 
mitigating the production of oxygen reactive species and  decreasing pro-apoptotic proteins, such as 
Bax. The knowledge of new agents capable of acting on the course of apoptosis  is important and 
valuable for developing further therapies against various diseases. Thus, the  objective of this review 
was to clarify the main aspects of cell death by apoptosis and the role of melatonin in this process
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system, the control of circadian rhythms for various physiological 
processes, and the anti-apoptotic system in various cell death-
induced vertebrate tissues9-12. However, the mechanism through 
which melatonin exerts its inhibitory effect on cell death remains 
unclear. This review initially summarizes the apoptotic process 
and pathways and the anti-apoptotic activity of melatonin 
through the inhibition of the apoptotic pathways and activation 
of the survival pathways.
apoptoSIS
The integrity and homeostasis of multicellular organisms 
requires various cellular and molecular mechanisms to function 
perfectly, such as the one engaged in planned cell death. In 
this process, cell population is rigorously controlled by genetic 
and biochemical factors, which are in charge of the activation 
of specific anti-apoptotic molecules13. The activation of these 
molecules that signal cell death causes typical morphological and 
ultrastructural alterations in the apoptosis process: cell retraction, 
loss of adhesion to the extracellular matrix and neighboring cells, 
chromatin condensation, DNA internucleosomal fragmentation 
and the formation of cytoplasmic blebs referred to as apoptotic 
bodies3,14. In this process, the plasma membrane remains whole, 
but undergoes structural alterations, such as the distribution of 
phosphatidylserine on the outer layer of the membrane, which 
is a signal for phagocyte recognition15. In this manner, the dead 
cell is quickly removed without leakage of cytoplasmic content, 
thus avoiding an intense inflammatory response6.
Generally, the inflammatory response is present at necrosis, 
a type of cell death which is morphologically and biochemically 
different from apoptosis, in which the injury to the cell causes 
increased volume, chromatin aggregation, cytoplasmic disorga-
nization and loss of plasma membrane integrity.  Consequently, 
there is leakage of cytoplasmic content, thus causing damage to 
neighboring cells and local inflammatory reaction3,6.
 
Apoptosis inducers and inhibitors
Various factors are able to induce the apoptosis process 
through the activation of pro-apoptotic molecules. Among these 
are DNA damage (caused by ionizing radiation or chemotherapic 
agents), growth factors and nutrient deprivation, thermal shock 
and intracellular buildup of toxic oxygen reactives16.
Apoptosis inhibitors modulate the activation of anti-apoptotic 
molecules. Among them, we underscore the factors of extra-
cellular matrix, zinc, some aminoacids and steroid and non-
steroid hormones16. 
 
Caspases: cell death-effector molecules 
The morphological alterations observed in cells undergoing 
apoptosis are the final result of the activation of enzymes referred 
to as caspases. These enzymes modulate the apoptotic process 
and serve as primary markers in apoptosis tests even before 
the morphological signs become evident. These enzymes are 
responsible for the cleavage of substrates that contain aspartic 
acid residue, such as the poly (ADP ribose) polymerase, enzymes, 
cell cycle regulating proteins, structural proteins, such as laminin 
and actin, among others13,17. In humans, more than 14 types 
of caspases are recognized, but part of them have pro-apoptotic 
properties13. Caspases-1, 4 and 5, for example, are recognized 
as being important in the inflammatory process, whereas 
caspases-2, 3 and 10 are mostly (if not exclusively) involved 
in apoptosis13.
Depending on the event in which they participate in the apop-
tosis process, caspases can be referred to as initiators (caspases 
8 and 10) or executors (caspases 3 and 7). Genetic studies 
show that apoptosis, just like any other metabolic process, can 
be interrupted by mutation2. In mice, for example, the deletion 
or mutation of the gene that encodes the Mrad1 protein, which 
plays a vital role in DNA repair and cell cycle control, results in 
the abolition of the planned cell death process, with the appea-
rance of skin tumors18.
Apoptosis activation pathways
Apoptosis can be initiated by external stimuli through the acti-
vation of specific receptors present on the cell surface (extrinsic 
pathway or cell death receptor pathway), referred to as death 
receptors, or by intracellular stress (intrinsic or mitochondrial 
pathway). Both pathways culminate with the activation of 
caspases that lead to cell death19,20. 
The extrinsic pathway is responsible for the elimination 
of undesirable cells during the development, maturation of 
the immune system and immune mediated tumor destruction 
(immune vigilance)17. This pathway is triggered by the interaction 
of specific ligands to a group of cognate receptors belonging to 
the family of the tumor necrosis factor (TNF), capable of causing 
the activation of caspase-3 and, consequently, cell death3,17. 
The receptor Fas (CD95/APO-1), a 45 kDa cell surface 
molecule belonging to the TNF family, has become a paradigm 
for studies on extrinsic pathway of apoptosis. Its ligand (Fas-L/ 
CD178) is a 37 kDa protein belonging to the superfamily of the 
TNFs 20-23. Fas and Fas-L are engaged in the cell death process; 
after the interaction of Fas-L on the cell surface with the Fas 
receptor, there is formation of aggregates in the form of trimers, 
which bond to adaptor protein FADD (Fas associated death 
domain) present in the cytoplasm. This molecular complex bonds 
to pro-caspase-8, resulting in the formation of the DISC (Death 
Inducing Signalling Complex) complex, where the activation 
(dimerization/cleavage) of pro-caspase-8 occurs, thus resulting 
in the activation of the effector caspase-3, which culminates in 
cell death17.
The intrinsic pathway is activated by intracellular or extra-
cellular stress, such as growth factor deprivation, DNA damage, 
hypoxia, and others. In response to these factors, the mitochon-
dria undergoes changes in its inner membrane potential, in terms 
of membrane permeability and increase of matrix density.  Addi-
tionally, some authors report that these organelles assume peri-
nuclear distribution during this process24. These mitochondrial 
alterations can be crucial for the triggering of death, and could 
facilitate the translocation of mitochondrial proteins, blockage 
of ATP synthesis and increase in the production of reactive 
oxygen species, which leads to the oxidation of lipids, proteins 
and nucleic acids, in addition to contributing to the activation 
of caspases-9 and 3. Mitochondrial derangement could also 
facilitate the release of cytochrome C to the cytoplasm, where 
it forms a complex with the activation factor associated with 
apoptosis-1 (APAF-1) and caspase-9, referred to as apoptosome, 
which promotes the cleavage of pro-caspase-9, thus releasing 
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active caspase-9, which is capable of activating caspase-3 and 
provoking apoptosis3,16,17. 
It should be mentioned that, in both pathways, the activation 
of caspase-3 is the crucial, irreversible point of the cell death 
phenomenon; i.e., at this stage there are no mechanisms capable 
of reversing apoptosis16.
 
Inhibitors of caspase activation in apoptosis
The recruitment and activation of pro-caspase-8 are regulated 
by molecules such as the FLIP (FLICE-like inhibitory protein), 
homolog of caspase-8 with important differences, such as the 
lack of catalytic residue, which renders it incapable of performing 
proteolytic activity.
The literature has not reached a consensus regarding the 
pro- or anti-apoptotic properties of FLIP.  Studies show that, 
when present at low levels (in normal cells), FLIP increases the 
activation of caspase-8; however, when there are high levels of 
the protein in tumor cells, it competes with caspase-8 for the 
bond site of the Fas-FADD complex, thus inhibiting apoptosis17,19.
It should be noted that some proteins in the Bcl-2 family 
also modulate the activation of caspases, whether inhibiting 
the activation of these proteases, such as Bcl-2, Bcl-xl, Bcl-w, 
or promoting apoptosis, such as Bax, Bax, Bid, Bak and Bcl-xs 
5, 24-27.
The Bcl-2 protein, for example, inhibits the release of cyto-
chrome C by the mitochondrias, thus preventing cell death11,12,25. 
However, although the antiapoptotic role of these proteins has 
been thoroughly documented, little is known about the precise 
mechanism through which Bcl-2 and the other members of this 
family can act in this process4.
 
Melatonin 
Melatonin (N-acetyl-5-metoxytryptamine) has already been 
used in medical practice for many years, being safe and well-
tolerated, even at high doses, thus easily crossing the blood-brain 
barrier27. In addition to being used to increase sleep efficiency28, 
treat jet lag, improve the cardiovascular system29, as an anti-
aging drug28, diet supplement, or as protection against the appe-
arance of tumors30, there is evidence that it could play a part in 
controlling the cell death process, acting in apoptosis11,12,31, 32.
 
Melatonin action in apoptosis
Several studies show that melatonin plays a part both in 
the extrinsic pathway, by modulating the expression of death 
receptors, and in the intrinsic pathway, by eliminating from the 
cytoplasm the oxidating free radicals that can be generated by 
the mitochondria. 
Some authors show an anti-apoptotic action of melatonin in 
different organs, such as thymus, kidney, brain and liver, attribu-
ting this mainly to its antioxidating properties7-12,33,34 when elimi-
nating radicals hydroxyl (OH-), peroxyl (ROO-) 26, superoxides4 
and cardiolipin oxidation from mitochondrias35. In the lacrimal 
glands of hamsters, this hormone prevents cell damage caused 
by the buildup of porphyrins, due to its capacity of decreasing the 
RNAm synthesis of aminolevulinate synthetase, enzyme involved 
in the production of porphyrins, and also due to increasing the 
levels of RNAm of antioxidating enzymes such as manganese 
superoxide dismutase (Mn-SOD) and copper-zinc superoxide 
dismutase (Cu-Zn-SOD)36. The synthesis of glutathione peroxi-
dase, another very important enzyme for the elimination of free 
radicals from the organism, also increases in the brains of mice 
treated with melatonin27, thus proving that this hormone also acts 
over other enzymes that provide protection against toxic reac-
tives. Melatonin is also capable of acting as an antioxidant when 
negatively regulating the levels of nitric oxide synthase, involved 
in the synthesis of nitric oxide, as observed in mice submitted to 
ischemic brain injury and treated with the hormone33. 
Some authors have reported that, as the melatonin levels 
decrease with aging, there would be an inhibition of the SIRTI 
gene that regulates circadian rhythm, thus leading to its derange-
ment, with apoptosis inhibition and increase in the susceptibility 
to tumors37. 
In another study involving the central nervous system  (CNS), 
Lima et al.38 have observed that the administration of melatonin 
to pinealectomized mice induced to epilepsy with pilocarpine 
caused a reduction in the number of TUNEL-positive cells in 
various limbic areas of the CNS. This indicates a neuroprotector 
effect of this hormone during the epileptic state, suggesting that 
it can be used as adjuvant in anticonvulsive therapy.  Wang39 
has reported that the melatonin action acts on the prevention of 
neurodegenerative diseases by inhibiting the intrinsic pathway 
of apoptosis and activating the survival pathways. 
The modulation of immune elements is also a mechanism 
through which melatonin can inhibit apoptosis, thus inducing 
the release of cytokines such as interleukin (IL)-4. Some authors 
have shown that melatonin is capable of avoiding cell death of 
hematopoietic progenitors after chemotherapy, both in vivo and in 
vitro, and that this effect is mediated by Th2-type T-cells, which 
are stimulated by this hormone to release IL-4, which induces 
the activation of stromal cells40. These cells, in turn, begin 
to release granulocyte macrophage colony-stimulating factor 
(GM-CSF), thus increasing the number of granulocyte macro-
phage (GM-CFU) colony forming units. However, it is important 
to observe that this effect takes place only with precursors of the 
GM-CFU lineage. Other studies have shown that melatonin is 
not capable of influencing tumor growth and the appearance of 
methastases41. However, when used as adjuvant in the treatment 
of cancer, it obtains good results in controlling the disease42.
Melatonin can also interact with nuclear receptors, exerting 
direct genomic action, altering the expression of apoptosis genes 
and thus inhibiting cell death.
In culture, melatonin inhibits the proliferation of human breast 
cancer cells (MCF-7), inducing a cell cycle arrest depending on 
an increase of protein p21WAF1 expression, which is mediated 
by pathway p53, thus disrupting the balance between mitosis 
and apoptosis43. On the other hand, in thymocytes treated with 
dexamethasone, it has been observed that the administration of 
melatonin was able to reverse the apoptotic process caused by 
the glycocorticoid, reducing DNA fragmentation and Bax (pro-
apoptotic protein of the Bax RNAm) levels10. In that sense, studies 
have shown that melatonin is capable of reducing the activity in 
caspases-9 and 3 induced buy the increased concentration of 
cytoplasmic calcium in human leukocytes, due to the activation 
of Bax with release of cytochrome C, thus leading to reduced 
apoptotic activity44.
As previously mentioned, the anti-apoptotic action of 
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melatonin has also been reported in nervous and renal tissues7; 
in this case, treatment with the hormone causes a decrease in 
the expression levels of proteins Fas, Fas-L and p-53, along with 
an increase in the expression of Bcl-211. However, the mecha-
nisms involved in the control of these genes’ expression, as well 
as the end of the apoptosis cascade (caspase-3-cleaved) require 
further investigation.
Considering the importance of the phenomenon of apoptosis 
in various proliferative affections, such as neoplasia, and other 
evidence of the melatonin action in the apoptotic process, this 
information is important to the formulation of future therapies 
for the clinical practice.
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